Nerandomilast

Adult Dosing .

Dosage forms:  TAB

Investigational New Drug (IND)

[pending FDA approval]

idiopathic pulmonary fibrosis

[indication/pt population pending FDA approval]

Info: inhibits phosphodiesterase type 4B (PDE4B), leading to increased intracellular cAMP levels

progressive pulmonary fibrosis

[indication/pt population pending FDA approval]

Info: inhibits phosphodiesterase type 4B (PDE4B), leading to increased intracellular cAMP levels

Peds Dosing .

Dosage forms:  --

Investigational New Drug (IND)

[pending FDA approval]

Info: not anticipated to be applicable to Peds population